Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonor Ribeiro

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Current Oncology (Toronto, Ont.)|August 28, 2024
Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE StudyMaria Margarida Teixeira, João Dias, Teresa André, et al.
Advances in Cancer Research|June 29, 2020
HER family in cancer progression: From discovery to 2020 and beyondRakesh Kumar, Bijesh George, Marcia R Campbell, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2021
Sustained Hippocampal Neural Plasticity Questions the Reproducibility of an Amyloid-β-Induced Alzheimer's Disease ModelSara L Paulo, Leonor Ribeiro-Rodrigues, Rui S Rodrigues, et al.
Future Science OA|February 7, 2020
Prognostic factors for patients treated with abirateroneCecília M Alvim, André Mansinho, Rita S Paiva, et al.
Frontiers in Oncology|October 29, 2024
Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck - ReCisTT studyAna Varges Gomes, Gilberto Castro, Thiago Bueno de Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2021
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II studyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Cancers|August 12, 2023
Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive EntitiesMiguel Esperança-Martins, Cecília Melo-Alvim, Sara Dâmaso, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|August 18, 2020
Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinomaCecília Melo-Alvim, Patrícia Miguel-Semedo, Rita Silva Paiva, et al.
Nature Communications|July 14, 2025
Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment responseCong Tang, Patrícia Corredeira, Sandra Casimiro, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Current Oncology (Toronto, Ont.)|August 28, 2024
Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE StudyMaria Margarida Teixeira, João Dias, Teresa André, et al.
Advances in Cancer Research|June 29, 2020
HER family in cancer progression: From discovery to 2020 and beyondRakesh Kumar, Bijesh George, Marcia R Campbell, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2021
Sustained Hippocampal Neural Plasticity Questions the Reproducibility of an Amyloid-β-Induced Alzheimer's Disease ModelSara L Paulo, Leonor Ribeiro-Rodrigues, Rui S Rodrigues, et al.
Future Science OA|February 7, 2020
Prognostic factors for patients treated with abirateroneCecília M Alvim, André Mansinho, Rita S Paiva, et al.
Frontiers in Oncology|October 29, 2024
Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck - ReCisTT studyAna Varges Gomes, Gilberto Castro, Thiago Bueno de Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2021
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II studyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
Cancers|August 12, 2023
Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive EntitiesMiguel Esperança-Martins, Cecília Melo-Alvim, Sara Dâmaso, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|August 18, 2020
Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinomaCecília Melo-Alvim, Patrícia Miguel-Semedo, Rita Silva Paiva, et al.
Nature Communications|July 14, 2025
Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment responseCong Tang, Patrícia Corredeira, Sandra Casimiro, et al.
Pageof 3